The record-breaking single-asset continuation fund was raised for health innovation platform Real Chemistry.
We map the fair value, cost, and acquisition timeline for one of evergreen capital's most invested-in Q2 continuation funds.
We dive into FLEX, outlining the performance, portfolio composition, and other details of the secondaries-focused tender offer fund, leveraging EvergreenLink Data.
We map the fair value, cost, and acquisition timeline for one of evergreen capital's most invested-in Q1 continuation funds.
We examine the Q1 capital flows, investment activity, and performance of the secondaries-focused tender offer fund, leveraging EvergreenLink Data.
The deal is part of a broader $2 billion recap that also attracted fresh capital from Bain Capital.
We examine the Q4 capital flows, deployment activity, and performance of the secondaries-focused tender offer fund, leveraging EvergreenLink Data.
We examine the Q4 capital flows, investment activity, and returns of the secondaries-focused tender offer fund, leveraging EvergreenLink Data.
Institutional Link maps the fair value, cost, acquisition timeline, and more details for one of evergreen capital's most invested-in Q4 continuation funds.
Institutional Link maps the fair value, cost, acquisition timeline, and more details for perpetual capital's most invested-in Q4 continuation fund.
